[Review of Innovative Pharmaceutical Companies] ⑫ ABL Bio, led by LO, faces the challenge of completing clinical trials

ABL Bio has signed a series of licensing deals with Sanofi, GSK, and Eli Lilly, boosting cash inflows and validating its platform.

However, its core pipelines have not yet reached approval or commercialization, so licensing wins have not translated into product success.

For partner-led assets, the company has limited control over trial timelines and regulatory strategy, while co-developed or in-house programs carry late-stage cost and failure risk.

In the end, ABL Bio’s long-term performance depends less on more deals and more on completing trials, winning approval, and realizing milestones and royalties.